Betamipron reduces cisplatin nephrotoxicity in rodents without modifying its antileukemic activity in mice

Renal Failure

Volumn 19, Issue 3, 1997, Pages 425-438

  Tokunaga, Jin ^a   Kobayashi, Mie ^a   Nakamura, Chizuko ^a   Kitagawa, Akira ^a   Arimori, Kazuhiko ^a   Nakano, Masahiro ^a  

^a KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Antileukemic activity; Betamipron; Cisplatin; N Benzoyl alanine; Nephrotoxicity

Indexed keywords

BETA 2 MICROGLOBULIN; BETAMIPRON; CISPLATIN; GAMMA GLUTAMYLTRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CELL PROTECTION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY PROXIMAL TUBULE; LEUKEMIA; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL TIME; UREA NITROGEN BLOOD LEVEL;

EID: 0030978991     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.3109/08860229709047728     Document Type: Article

References (39)

1. Madias NE, Harrington JT: Platinum nephrotoxicity. Am J Med 65:307-314, 1978.
2. Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozenc weig M, Young RC, Muggia FM: Toxic effects of cij-dichlorodiammineplatinum(II) in man. Cancer Treat Rep 63:1527-1531, 1979.
3. Raghavan D, Pearson B, Dubai P, Rogers J, Meagher M, Wines R, Mameghan H, Boulas J, Green D: Initial intravenous c/j-platinum therapy: improved management for invasive high risk bladder cancer. J Urol 133:399-402, 1985.
4. Krakoff IH, Lippman AJ: Clinical trials of rà-platinum(II) diaminodichloride (PDD) in patients with advanced cancer. Recent Results Cancer Res 48:183-190, 1974.
5. Merrin CE: Treatment of genitourinary tumors with cw-dichlorodiammineplatinum(II): experience in 250 patients. Cancer Treat Rep 63:1579-1584, 1979.
6. Aamdal S, Fodstad O, Pihl A: Some procedures to reduce cw-platinum toxicity reduce antitumor activity. Cancer Treat Rev 14:389-395, 1987.
7. Sugiyama K, Yokota M, Ueda H, Ichio Y: Protective effects of Kampo medicines against m-diamminedichloroplatinum(II)-induced nephrotoxicity and bone marrow toxicity in mice. J Med Pharm Soc \VakanYaku 10:76-85, 1993.
8. Hayashi T, Watanabe Y, Kumano K, Kitayama R, Muratani T, Yasuda T, Saikawa I, Katahira J, Kumada T, Shimizu K: Protective effect of piperacillin against the nephrotoxicity of cisplatin in rats. Antimicrob Agents Chemother 33:513-518, 1989.
9. Hori R, Ishikawa Y, Takano M, Okano T, Kitazawa S, Inui K: The interaction of cephalosporin antibiotics with renal cortex of rats: accumulation to cortical slices and binding to purified plasma membranes. Biochem Pharmacol 31:2267-2272, 1982.
10. Ross DA, Gale OR: Reduction of the renal toxicity of cu-dichlorodiammineplatinum(II) by probenecid. Cancer Treat Rep 63:781-787, 1979.
11. Jacobs C, Coleman CN, Rich L, Hirst K, Weiner MW: Inhibition of ci's-diamminedichloroplatinum secretion by the human kidney with probenecid. Cancer Res 44:3632-3635, 1984.
12. Jacobs C, Kaubisch S, Halsey J: The use of probenecid as a chemoprotector against cisplatin nephrotoxicity. Cancer 67:1518-1524, 1991.
13. Naganuma H, Tokiwa H, Hirouchi Y, Kawahara Y, Fukushige J, Fukami M, Hirota K, Muramatsu S, Takahagi H, Inui K, Tanigawara Y, Yasuhara M, Hori R, Kuwahara S: Nephroprotective effect and its mechanism of betamipron (1): relationships of renal transport. Chemotherapy 39(S-3):166-177, 1991.
14. Naganuma H, Hirouchi Y, Kawahara Y, Inui K, Tanigawara Y, Yasuhara M, Hori R, Kuwahara S: Nephroprotective effect and its mechanism of betamipron (2): relationships of renal excretion. Chemotherapy 39(S-3):178-189, 1991.
15. Kimura K, Totsuka S, Saito T, Mori M: Toxicological studies of panipenem/betamipron: acute toxicity studies in rats with a single intravenous administration. Chemotherapy 39(S-3):140-143, 1991.
16. Hirouchi Y, Naganuma H, Kawahara Y, Okada R, Kamiya A, Inui K, Hori R: Protective effect of W-acyl amino acids (NAAs) on cephaloridine (CER) nephrotoxicity in rabbits. Jpn J Pharmacol 63:487-493, 1993.
17. Tokunaga J, Kobayashi M, Nakamura C, Kitagawa A, Arimori K, Nakano M: Protective effect of W-benzoyl-ß-alanine against cisplatin nephrotoxicity in rats. Renal Failure 18:225-240, 1996.
18. Choie DD, Longnecker DS, del Campo AA: Acute and chronic cisplatin nephropathy in rats. Lab Invest 44:397-402, 1981.
19. Levine BS, Henry MC, Port CD, Richter WR, Urbanek MA: Nephrotoxic potential of m-diamminedichloroplatinum and four analogs in male Fischer 344 rats. J Nail Cancer Inst 67:201-206, 1981.
20. Ward JM, Fauvie KA: The nephrotoxic effects of cii-diammine-dichloroplatinum(ll) (NSC-119875) in male F344 rats. Toxicol Appl Pharmacol 38:535-547, 1976.
21. Zunino F, Pratesi G, Micheloni A, Cavalletti E, Sala F, Tofanetti O: Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. Chem-Biol Interact 70:89-101, 1989.
22. Hanigan MH, Gallagher BC, Taylor PT Jr, Large MK: Inhibition of y-glutamyl transpeptidase activity by acivicin m vivo protects the kidney from cisplatin-induced toxicity. Cancer Res 54:5925-5929, 1994.
23. Umeki S, Watanabe M, Yagi S, Soejima R: Supplemental fosfomycin and/or steroids that reduce cisplatininduced nephrotoxicity. Am J Med Sci 295:6-10, 1988.
24. Leyland-Jones B, Morrow C, Täte S, Urmacher C, Gordon C, Young CW: ci-Diamminedichloroplatinum(II) nephrotoxicity and its relationship to renal -y-glutamyl transpeptidase and glutathione. Cancer Res 43:6072-6076, 1983.
25. Kinsella JL, Holohan PD, Pessah NI, Ross CR: Transport of organic ions in renal cortical luminal and antiluminal membrane vesicles. J Pharmacol Exp Ther 209:443-450, 1979.
26. Holohan PD, Ross CR: Mechanisms of organic cation transport in kidney plasma membrane vesicles. II. A pH studies. J Pharmacol Exp Ther 216:294-298, 1981.
27. Rennick BB: Renal transport of organic cations. Am J Physiol 240:F83-F89, 1981.
28. Hsyu PH, Giacomini KM: The pH gradient-dependent transport of organic cations in the renal brush-border membrane. J Biol Chem 262:3964-3968, 1987.
29. Gisclon L, Wong FM, Giacomini KM: Cimetidine transport in isolated luminal membrane vesicles from rabbit kidney. Am J Physiol 253:F141-F150, 1987.
30. Mckinney TD, Myers P, Speeg KV Jr: Cimetidine secretion by rabbit renal tubules in vitro. Am J Physiol 241:F69-F76,1981.
31. Cacini W, Keller MB, Grund VR: Accumulation of cimetidine by kidney cortex slices. J Pharmacol Exp Ther 221:342-346, 1982.
32. Hsyu PH, Gisclon LG, Hui AC, Giacomini KM: Interactions of organic anions with the organic cation transport in renal BBMV. Am J Physiol 254:F56-F61, 1988.
33. Hayashi T, Watanabe Y, Kumano K, Kitayama R, Yasuda T, Saikawa I, Katahira J, Kumada T, Shimizu K: Protective effect of piperacillin against nephrotoxicity of cephaloridine and gentamicin in animals. Antimicrob Agents Chemolher 32:912-918, 1988.
34. Pugh D, Walker PG: The localization of W-acetyl-ß-D-glucosaminidase in tissues. J Histochem Cytochem 9:242-250, 1961.
35. Lockwood TD, Bosmann HB: The use of urinary W-acetyl-ß-D-glucosaminidase in human renal toxicology. II. Elevation in human excrétion after aspirin and sodium salicylate. ToxicolAppl Pharmacol 49:337-345, 1979.
36. Jones BR, Bhalla RB, Mladek J, Kaleya RN, Gralla RJ, Alock NW, Schwartz MK, Young CW, Reidenberg MM: Comparison of methods of evaluating nephrotoxicity of cw-platinum. Clin Pharmacol Ther 27:557562, 1980.
37. Levi FA, Hrushesky WJM, Blomquist CH, Lakatua DJ, Haus E, Halberg F, Kennedy BJ: Reduction of cisdiamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing. Cancer Res 42:950955, 1982.
38. Gandara DR, Mansour R, Wold H, George C: Dose-limiting myelosuppression associated with high-dose cisplatin (200 mg/m2) in hypertonic saline. Cancer Treat Rep 70:820-821, 1986.
39. Schweitzer VG: Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Laryngoscope 103:1-52, 1993.